These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
624 related articles for article (PubMed ID: 23700062)
1. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia. Henze G; v Stackelberg A; Eckert C Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062 [TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029 [TBL] [Abstract][Full Text] [Related]
3. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol. Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691 [TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324 [TBL] [Abstract][Full Text] [Related]
5. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458 [TBL] [Abstract][Full Text] [Related]
6. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972 [TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714 [TBL] [Abstract][Full Text] [Related]
8. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027 [TBL] [Abstract][Full Text] [Related]
9. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Locatelli F; Zecca M; Messina C; Rondelli R; Lanino E; Sacchi N; Uderzo C; Fagioli F; Conter V; Bonetti F; Favre C; Porta F; Giorgiani G; Pession A Leukemia; 2002 Nov; 16(11):2228-37. PubMed ID: 12399966 [TBL] [Abstract][Full Text] [Related]
10. [The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group]. Chybicka A; Bogusławska-Jaworska J; Gorczyńska E; Juszczak K; Armata J; Balcerska A; Balwierz W; Bubała H; Filiks-Litwin B; Kołecki P; Kowalczyk J; Lukowska K; Matysiak M; Rokicka-Milewska R; Rola-Kurc E; Stencel D; Sońta-Jakimczyk D; Strojny W; Wachowiak J; Wieczorek M; Wysocki M; Zelenay E Wiad Lek; 1998; 51 Suppl 4():25-32. PubMed ID: 10731940 [TBL] [Abstract][Full Text] [Related]
11. Prediction of outcome by early response in childhood acute lymphoblastic leukemia. Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057 [TBL] [Abstract][Full Text] [Related]
12. [Results and experiences with a modified BFM protocol for treatment of recurrences in children with acute lymphoblastic leukemia in East German areas]. Sauerbrey A; Zintl F; Malke H; Reimann M; Maaser M; Domula M; Dörffel W; Eggers G; Exadaktylos P; Kotte W Klin Padiatr; 1993; 205(4):281-7. PubMed ID: 8377448 [TBL] [Abstract][Full Text] [Related]
13. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271 [TBL] [Abstract][Full Text] [Related]
16. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576 [TBL] [Abstract][Full Text] [Related]
17. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial. Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]. Sun XF; Jiang WQ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Li YH; Zhou ZM; Zhen ZJ; Xia Y; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1687-91. PubMed ID: 15601561 [TBL] [Abstract][Full Text] [Related]
19. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy. Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303 [TBL] [Abstract][Full Text] [Related]
20. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]